Fate Therapeutics (FATE) Citi's 2024 Global Healthcare Conference summary

Key scientific and clinical advances

• Major focus on overcoming allogeneic and autoimmune rejection in cell and gene therapy, with progress in both animal models and early human studies.

• Off-the-shelf CAR T therapies are advancing in oncology and autoimmune diseases, with pivotal trials and new indications such as lupus and type 1 diabetes on the horizon.

• Innovations include gene editing to knock out MHC class I/II and overexpress CD47, and using iPSC-derived NK and T cells for scalable, consistent, and cost-effective therapies.

• HLA matching strategies in allogeneic CAR T trials show improved patient outcomes, with confirmatory cohorts and phase 3 planning underway.

• In vivo CAR T platforms are being developed to enable immune reset without chemotherapy, with preclinical safety and delivery data supporting future clinical translation.

Competitive landscape and differentiation

• Off-the-shelf approaches are seen as critical for broader patient access, especially in autoimmune settings where apheresis is challenging.

• iPSC-derived cell banks enable uniform, high-purity products at lower cost, with the potential for large-scale, community-based deployment.

• Multiplexed gene editing and immune cloaking strategies are being used to enhance efficacy, persistence, and safety in both solid tumors and hematologic malignancies.

• Allogeneic CAR T cells are positioned to rival or surpass autologous products and bispecifics in efficacy, accessibility, and cost.

• Companies are leveraging oncology experience to inform autoimmune programs, with cross-indication learnings on trafficking, potency, and immune reset.

Pipeline updates and upcoming milestones

• Key upcoming data readouts include off-the-shelf CAR T in lupus, type 1 diabetes, large B cell lymphoma, multiple myeloma, and solid tumors.

• New confirmatory cohorts and phase 3 trials are planned for lead CAR T programs, with HLA matching strategies being validated.

• In vivo CAR T and gene-modified islet cell programs are advancing toward clinical data, with manufacturing and regulatory milestones ahead.

• Partnerships with academic and industry collaborators are supporting development in both autoimmune and oncology indications.

• Companies are well-funded into 2026 but anticipate the need for additional capital or partnerships to support late-stage development.